Advertisement

Drug Safety

, Volume 27, Issue 10, pp 745–756 | Cite as

Haematological Effects of Interferon-β-1a (Rebif®) Therapy in Multiple Sclerosis

  • Peter RieckmannEmail author
  • Paul O’Connor
  • Gordon S. Francis
  • Graham Wetherill
  • Enrica Alteri
Original Research Article

Abstract

Introduction: Interferon-β-Abstract-1a (Rebif®) is an established treatment for relapsing-remitting multiple sclerosis (MS) and haematological changes are commonly reported in clinical trials of this agent. The combined clinical trial and postmarketing safety database for subcutaneous interferon-β-1a (Rebif®) allows a comprehensive, retrospective assessment of both common and infrequent haematological effects associated with interferon-β therapy.

Methods: Haematological laboratory abnormalities were analysed from six randomised, controlled clinical trials of subcutaneous interferon-β-1a in MS, five of which were placebo-controlled. Treatment data were collected from 2482 patients for up to 6 months, 1178 patients for up to 2 years and 786 patients for up to 6 years. Total interferon-β-1a doses ranged from 22μg once weekly to 44μg three times weekly. Postmarketing surveillance data were also analysed.

Results: Treatment with interferon-β-1a led to asymptomatic dose-related reductions in all cell lineages under investigation, predominantly white blood cells. The greatest differences between interferon-β-1a therapy and placebo were seen for total leucocyte and neutrophil counts. At least two-thirds of patients affected by cytopenia experienced the onset of cytopenia within the first 6 months of therapy. The majority of events were mild and generally resolved within 3–4 months, while continuing therapy. Dose reductions were uncommon and only a small proportion (6 of 727; 0.8%) of patients stopped treatment over 2 years because of haematological abnormalities when receiving the highest dose of interferon-β-1a, 44μg three times weekly. Postmarketing safety reports were similarly related to asymptomatic cytopenias, although one case of potentially related autoimmune haemolytic anaemia was reported.

Conclusion: Although haematological abnormalities are common and dose-related in patients with MS receiving interferon-β-1a, the events are mainly mild and transient, with little impact on adherence to therapy. Haematological events are rarely of clinical significance and do not adversely affect the benefit-to-risk ratio that favours high-dose interferon-β-1a therapy.

Keywords

Multiple Sclerosis Lymphopenia Autoimmune Haemolytic Anaemia Haematological Abnormality Rebif 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The authors wish to express thanks to the patients who have participated in the studies, contributing data to this analysis and to the physicians and other study site personnel responsible for their care. Studies from which data have been utilised include PRISMS, SPECTRIMS, ETOMS, OWIMS, Nordic SPMS and EVIDENCE. Sarah-Jane Blake, Caudex Medical Ltd, provided valuable manuscript assistance.

Drs Rieckmann and O’Connor have received funding for research activities and honoraria for lectures and advisory panels from the manufacturer of Rebif®; Drs Francis and Alteri are employees of Serono; Dr Wetherill provided consultant statistical input to Serono.

References

  1. 1.
    PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628–36Google Scholar
  2. 2.
    Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285–94PubMedCrossRefGoogle Scholar
  3. 3.
    The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655–61Google Scholar
  4. 4.
    Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon β-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002; 59: 1496–506PubMedCrossRefGoogle Scholar
  5. 5.
    European Study Group on Interferon β-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491–7Google Scholar
  6. 6.
    Bayas A, Rieckmann P. Managing the adverse effects of interferon-β therapy in multiple sclerosis. Drug Saf 2000; 22(2): 149–59PubMedCrossRefGoogle Scholar
  7. 7.
    Walther EU, Hohfeld R. Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology 1999; 53: 1622–7PubMedCrossRefGoogle Scholar
  8. 8.
    Once Weekly Interferon for MS Study Group. Evidence of interferon B-1a dose response in relapsing-remitting MS. Neurology 1999; 53: 679–86Google Scholar
  9. 9.
    Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357: 1576–82PubMedCrossRefGoogle Scholar
  10. 10.
    Francis G, Grumser Y, Alteri E. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf 2003; 26(11): 815–27PubMedCrossRefGoogle Scholar
  11. 11.
    SPECTRIMS Study Group, Hughes RAC. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001; 56: 1496–504Google Scholar
  12. 12.
    Sorensen PS, Andersen O, Elovaara I, et al. Double-blind placebo-controlled study of once weekly, low dose interferon beta-1a in secondary progressive multiple sclerosis (SPMS): Nordic SPMS study [abstract]. Mult Scler 2001; 7Suppl. 1: S94Google Scholar
  13. 13.
    Rebif integrated summary of safety. Serono (Data on file)Google Scholar
  14. 14.
    Toccaceli F, Rosati S, Scuderi M, et al. Leukocyte and platelet lowering by some interferon types during viral hepatitis treatment. Hepato Gastroenterology 1998; 45: 1748–52PubMedGoogle Scholar
  15. 15.
    Ernstoff MS, Lembersky BC, Kirkwood JM. Fluorouracil, interferon-alpha, and colon cancer: rational pursuit of synergism between antimetabolites and biologicals. J Clin Oncol 1989; 7: 1764–5PubMedGoogle Scholar
  16. 16.
    Gugliotta L, Bagnara GP, Catani L, et al. In vivo and in vitro inhibitory effect of α-interferon on megakaryocyte colony growth in essential thrombocythaemia. Br J Haematol 1989; 71: 177–81PubMedCrossRefGoogle Scholar
  17. 17.
    Rotondi M, Mazziotti G, Biondi B, et al. Long-term treatment with interferon-β therapy for multiple sclerosis and occurrence of Graves’ disease. J Endocrinol Invest 2000; 23: 321–4PubMedGoogle Scholar
  18. 18.
    McDonald MD, Pender MP. Autoimmune hypothyroidism associated with interferon beta-1b treatment in two patients with multiple sclerosis. Aust N Z J Med 2000; 30: 278–9PubMedCrossRefGoogle Scholar
  19. 19.
    Durelli L, Ferrero B, Oggero A, et al. Autoimmune events during interferon beta-1b treatment of multiple sclerosis. J Neurol Sci 1999; 162: 74–83PubMedCrossRefGoogle Scholar
  20. 20.
    Duchini A. Autoimmune hepatitis and interferon beta-1a for multiple sclerosis. Am J Gastroenterol 2002; 97: 767–8PubMedCrossRefGoogle Scholar
  21. 21.
    Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994; 10: 115–50PubMedCrossRefGoogle Scholar
  22. 22.
    Sevastianos VA, Deutsch M, Dourakis SP, et al. Pegylated interferon α-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C. Am J Gastroenterol 2003; 98: 406–707CrossRefGoogle Scholar
  23. 23.
    Sagir A, Wettstein M, Heintges T, et al. Autoimmune thrombocytopenia induced by PEG-IFN-a 2b plus ribavirin in hepatitis C. Dig Dis Sci 2002; 47: 562–3PubMedCrossRefGoogle Scholar
  24. 24.
    Tomita N, Motomura S, Ishigatsubo Y. Interferon-alpha-induced pure red cell aplasia following chronic myelogenous leukemia. Anticancer Drugs 2001; 12: 7–8PubMedCrossRefGoogle Scholar
  25. 25.
    Landau A, Castera L, Buffet C, et al. Acute autoimmune hemolytic anemia during interferon alpha therapy for chronic hepatitis C. Dig Dis Sci 1999; 44: 1366–7PubMedCrossRefGoogle Scholar
  26. 26.
    Kazuta Y, Watanabe N, Sagawa K, et al. A case of autoimmune hemolytic anemia induced by IFN-β therapy for type-C chronic hepatitis. Fukushima J Med Sci 1995; 41: 43–9PubMedGoogle Scholar
  27. 27.
    Aslam AK, Singh T. Aplastic anemia associated with interferon β-1a. Am J Ther 2002; 9: 522–3PubMedCrossRefGoogle Scholar
  28. 28.
    Hrstkova H, Bajer M, Michalek J. Recombinant human interferon α-2a therapy in children with chronic immune thrombocytopenic purpura. J Pediatr Hematol Oncol 2002; 24: 299–303PubMedCrossRefGoogle Scholar
  29. 29.
    Cesana C, Brando B, Boiani E, et al. Effective treatment of autoimmune hemolytic anemia and hairy cell leukemia with interferon-α. Eur J Haematol 2002; 68: 120–1PubMedCrossRefGoogle Scholar
  30. 30.
    Barel C, Bilger K, Ninet J, et al. Treatment of hepatitis C virus-associated thrombocytopenic purpura with a combination of interferon alpha-2b and ribavirin. J Clin Gastroenterol 2002; 35: 200–1PubMedCrossRefGoogle Scholar
  31. 31.
    Rajan S, Liebman HA. Treatment of hepatitis C related thrombocytopenia with interferon alpha. Am J Hematol 2001; 68: 202–9PubMedCrossRefGoogle Scholar
  32. 32.
    Dikici B, Bosnak M, Kara IH, et al. Interferon-alpha therapy in idiopathic thrombocytopenic purpura. Pediatr Int 2001; 43: 577–80PubMedCrossRefGoogle Scholar
  33. 33.
    Donato H, Kohan R, Picon A, et al. α-Interferon therapy induces improvement of platelet counts in children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2001; 23: 598–603PubMedCrossRefGoogle Scholar
  34. 34.
    Vianelli N, Gugliotta L, Tura S, et al. Interferon-α2a treatment in a pregnant woman with essential thrombocythemia. Blood 1994; 83: 874–5PubMedGoogle Scholar
  35. 35.
    Berlex Laboratories. Betaseron® (interferon beta-1b) [package insert]. Berlex Laboratories, 2003Google Scholar
  36. 36.
    Panitch H. Differences between IFN beta-1A 44μg tiw and 30μg qw sustained to 16 months: final evidence results [abstract]. Int J MS Care 2003; 5: 80Google Scholar
  37. 37.
    Sandberg M. Comparative risk-benefit analysis in EVIDENCE [abstract]. Mult Scler 2003; 9: S139Google Scholar
  38. 38.
    Serono International. Rebif® (interferon beta-1a) [package insert]. Serono International, 2003Google Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Peter Rieckmann
    • 1
    Email author
  • Paul O’Connor
    • 2
  • Gordon S. Francis
    • 3
  • Graham Wetherill
    • 4
    • 5
  • Enrica Alteri
    • 6
  1. 1.Department of NeurologyWurzburgGermany
  2. 2.St Michaels Hospital, University of TorontoTorontoCanada
  3. 3.Neurology Clinical Development, Serono Inc.RocklandUSA
  4. 4.Biostatistics, Serono InternationalGenevaSwitzerland
  5. 5.Biometric Solutions LtdSt IvesUK
  6. 6.Worldwide Clinical Safety and Pharmacovigilance, Serono InternationalGenevaSwitzerland

Personalised recommendations